1. Home
  2. HRMY vs CCOI Comparison

HRMY vs CCOI Comparison

Compare HRMY & CCOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • CCOI
  • Stock Information
  • Founded
  • HRMY 2017
  • CCOI 1999
  • Country
  • HRMY United States
  • CCOI United States
  • Employees
  • HRMY N/A
  • CCOI N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • CCOI Telecommunications Equipment
  • Sector
  • HRMY Health Care
  • CCOI Consumer Discretionary
  • Exchange
  • HRMY Nasdaq
  • CCOI Nasdaq
  • Market Cap
  • HRMY 2.1B
  • CCOI 2.4B
  • IPO Year
  • HRMY 2020
  • CCOI N/A
  • Fundamental
  • Price
  • HRMY $35.99
  • CCOI $36.88
  • Analyst Decision
  • HRMY Strong Buy
  • CCOI Buy
  • Analyst Count
  • HRMY 9
  • CCOI 6
  • Target Price
  • HRMY $55.33
  • CCOI $49.17
  • AVG Volume (30 Days)
  • HRMY 531.4K
  • CCOI 1.9M
  • Earning Date
  • HRMY 10-28-2025
  • CCOI 08-07-2025
  • Dividend Yield
  • HRMY N/A
  • CCOI 11.04%
  • EPS Growth
  • HRMY 58.41
  • CCOI N/A
  • EPS
  • HRMY 3.10
  • CCOI N/A
  • Revenue
  • HRMY $772,527,000.00
  • CCOI $921,889,000.00
  • Revenue This Year
  • HRMY $20.09
  • CCOI $5.37
  • Revenue Next Year
  • HRMY $16.74
  • CCOI $6.45
  • P/E Ratio
  • HRMY $11.61
  • CCOI N/A
  • Revenue Growth
  • HRMY 17.74
  • CCOI N/A
  • 52 Week Low
  • HRMY $26.47
  • CCOI $29.62
  • 52 Week High
  • HRMY $41.61
  • CCOI $86.76
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 47.09
  • CCOI 41.23
  • Support Level
  • HRMY $36.50
  • CCOI $35.31
  • Resistance Level
  • HRMY $38.28
  • CCOI $38.48
  • Average True Range (ATR)
  • HRMY 0.95
  • CCOI 1.46
  • MACD
  • HRMY -0.17
  • CCOI 0.41
  • Stochastic Oscillator
  • HRMY 9.84
  • CCOI 40.57

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About CCOI Cogent Communications Holdings Inc.

Cogent carries over one fifth of the world's internet traffic over its network and is a broadband provider for businesses. Cogent's corporate customers are in high-rise office buildings, where the firm provides two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for nearly half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.

Share on Social Networks: